Main Street Family Pharmacy voluntarily surrenders license in LA

Main Street Family Pharmacy, LLC, dba Main Street

Family Pharmacy (PHY.006371-NR): Accepted voluntary

surrender, resulting in active suspension of the

pharmacy permit for an indefinite period of time, effective

December 12, 2013.
quoted from here

Louisiana Board of Pharmacy Suspends Precision Pharmacy!!! Suspends the execution for three years and places on probation for 3 years--10,000 fine

Precision Pharmacy, LLC, dba Precision Pharmacy

(PHY.006219-NR): Suspended the pharmacy permit

for three years and suspended the execution of the suspension,

then placed the pharmacy permit on probation

for three years, effective February 12, 2012, subject to

certain terms enumerated in the consent agreement, and

further, assessed a fine of $10,000 plus administrative

costs; for four counts, including shipping prescription

medications to Louisiana without a permit.
quoted from here

Louisiana Board of Pharmacy Disciplinary Action

Disciplinary Actions (14-04-462)

During its November 2013 meeting, the Board took final

action in the following matters:

Charlene Marie Fletcher (CPT.004539): Formal Hearing

– Revoked the certificate, and further, assessed a

fine of $5,000 plus administrative, investigative, and

hearing costs; for seven counts, including diversion of

controlled substances (CS) from her employer pharmacy.

Louisiana Board of Pharmacy Status Report on Rulemaking

Status Report on Rulemaking

Activities (14-04-461)

The Board continues to promulgate new rules as well

as revisions to existing rules. For its clients who have

given the Board their e-mail addresses, the Board sends

electronic Notices of Rulemaking Activity about these

activities.

♦♦Regulatory Project 2013-1 ~ Compounding for Prescriber

Use. The Board has republished the emergency

rule that places limits on the amount of compounding

for prescriber use a pharmacy may prepare without

a patient-specific prescription. The Board’s Regulation

Revision Committee is working on a proposal

that includes new legislative language and includes

some of the comments and testimony from the public

hearing. You can follow the progress of that proposal

in the Public Notices section of the Board’s website.

♦♦Regulatory Proposal 2014-A ~ PMP Delegates. The

Board gave preliminary approval to this proposal,

which will authorize prescribers and dispensers to

appoint delegates for the purpose of retrieving information

about their patients from the Prescription

Monitoring Program (PMP) database, but only according

to rules promulgated by the Board for that

purpose. The Board will conduct a public hearing

to receive comments and testimony on the proposal.

Look for the electronic Notice of Rulemaking Activity

for the specific date of the hearing. You can follow the

progress of this proposal in the Public Notices section

of the Board’s website.

♦♦Regulatory Proposal 2014-B ~ Veterinarian Exclusion

from PMP. The Board gave preliminary approval to

this proposal, which will exclude veterinarians from

participating in the PMP. The Board will conduct a

public hearing to receive comments and testimony on

the proposal. Look for the electronic Notice of Rulemaking

Activity for t he specific d ate of t he hearing.

You can follow the progress of this proposal in the

Public Notices section of the Board’s website.
quoted from here

Louisiana Board of Pharmacy April 2014 Newsletter

read here

Arizona Board of Pharmacy April 2014 Newsletter

read here

Critical Analysis: The Risk of Counterfeit Pharmaceuticals and How to Stem the Flow

Posted on 02 April 2014. Tags: counterfeit, drugs, pharmaceutical, World Health Organization

Though the term is defined differently in different countries, the World Health Organization (WHO) has come up with a working definition of what constitutes a counterfeit drug in an effort to understand the global implications of counterfeit pharmaceuticals and to facilitate the exchange of information between countries regarding this issue.  An estimated 5% of world trade in branded products is counterfeit. Pharmaceuticals are an attractive product for counterfeiting for a variety of factors, the most problematic of which are the difficulty in detecting counterfeits, and lack of a global standard system of enforcement.

continue to read here

New USP Webpage Answers Common Questions About 795 and 797

New USP Webpage Answers Common

Questions About USP Chapters <795>

and <797>

In response to questions concerning United States Pharmacopeia-

National Formulary (USP-NF) General Chapters <795> and

<797>, USP has created a new frequently asked questions (FAQs)

page on its website. The FAQs answer questions related to the Revision

Bulletin for Chapter <795> that was issued on November 22,

2013, and became official on January 1, 2014. Among other topics,

the FAQs address common questions regarding beyond-use dating

and the differences between testing stability with strength (potency)

or stability-inducing methods. The FAQs can be accessed at www

.usp.org/support-home/frequently-asked-questions/compounding.

Question four on the page includes a link to a USP article, “Strength

and Stability Testing for Compounded Preparation
quoted from here

South Dakota Board of Pharmacy April 2014 Newsletter

read here

Texas executions stayed by federal judge over state's lethal drug source

State must provide inmates with information about the source of the drugs it will use to put them to death, judge rules

 

A federal judge in Houston has stopped two imminent Texas executions because state officials refused to reveal key details about the drugs to be used to put the inmates to death.
District judge Vanessa Gilmore issued a temporary injunction on Wednesday ordering Texas to provide the lawyers representing inmates Tommy Sells and Ramiro Hernandez-Llanas with information about the supplier and quality of a new batch of pentobarbital, a barbiturate that is to be used in the lethal injections.

continue to read here